[1]
Jones CM, Christensen A, Gladden RM. Increases in prescription opioid injection abuse among treatment admissions in the United States, 2004-2013. Drug and alcohol dependence. 2017 Jul 1:176():89-95. doi: 10.1016/j.drugalcdep.2017.03.011. Epub 2017 May 16
[PubMed PMID: 28531769]
[2]
Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. Harm reduction journal. 2017 May 12:14(1):29. doi: 10.1186/s12954-017-0153-2. Epub 2017 May 12
[PubMed PMID: 28532488]
[3]
Love SA, Lelinski J, Kloss J, Middleton O, Apple FS. Heroin-related Deaths from the Hennepin County Medical Examiner's Office from 2004 Through 2015. Journal of forensic sciences. 2018 Jan:63(1):191-194. doi: 10.1111/1556-4029.13511. Epub 2017 Apr 19
[PubMed PMID: 28422290]
[4]
Darke S, Duflou J. The toxicology of heroin-related death: estimating survival times. Addiction (Abingdon, England). 2016 Sep:111(9):1607-13. doi: 10.1111/add.13429. Epub 2016 Jun 1
[PubMed PMID: 27082514]
[5]
Roxburgh A, Darke S, Salmon AM, Dobbins T, Jauncey M. Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. Drug and alcohol dependence. 2017 Jul 1:176():126-132. doi: 10.1016/j.drugalcdep.2017.02.027. Epub 2017 May 17
[PubMed PMID: 28535454]
[6]
Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999-2015. NCHS data brief. 2017 Feb:(273):1-8
[PubMed PMID: 28256996]
[7]
LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. European journal of pharmacology. 2000 Dec 27:410(2-3):249-268
[PubMed PMID: 11134674]
[8]
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacological reviews. 2005 Mar:57(1):1-26
[PubMed PMID: 15734726]
[9]
Bazoukis G, Spiliopoulou A, Mourouzis K, Grigoropoulou P, Yalouris A. Non-cardiogenic pulmonary edema, rhabdomyolysis and myocardial injury following heroin inhalation: a case report. Hippokratia. 2016 Jan-Mar:20(1):84-87
[PubMed PMID: 27895451]
Level 3 (low-level) evidence
[10]
Riccardello GJ Jr, Maldjian PD. Pulmonary hemorrhage in acute heroin overdose: a report of two cases. Emergency radiology. 2017 Dec:24(6):709-712. doi: 10.1007/s10140-017-1531-5. Epub 2017 Jul 4
[PubMed PMID: 28674923]
Level 3 (low-level) evidence
[11]
Büttner A, Mall G, Penning R, Weis S. The neuropathology of heroin abuse. Forensic science international. 2000 Sep 11:113(1-3):435-42
[PubMed PMID: 10978659]
[12]
Jones JD, Campbell A, Metz VE, Comer SD. No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. Addictive behaviors. 2017 Aug:71():104-106. doi: 10.1016/j.addbeh.2017.03.008. Epub 2017 Mar 9
[PubMed PMID: 28325710]
[13]
Pavarin RM, Fioritti A, Sanchini S. Mortality trends among heroin users treated between 1975 and 2013 in Northern Italy: Results of a longitudinal study. Journal of substance abuse treatment. 2017 Jun:77():166-173. doi: 10.1016/j.jsat.2017.02.009. Epub 2017 Feb 23
[PubMed PMID: 28237351]
[14]
Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F, Boardman K, Davies DK, O'Brien CP, Ling W, Kleber H, Herman BH. A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug and alcohol dependence. 2008 Sep 1:97(1-2):158-68. doi: 10.1016/j.drugalcdep.2008.04.002. Epub 2008 May 27
[PubMed PMID: 18508207]
Level 1 (high-level) evidence
[15]
Rounsaville BJ, Kosten TR. Treatment for opioid dependence: quality and access. JAMA. 2000 Mar 8:283(10):1337-9
[PubMed PMID: 10714736]
Level 2 (mid-level) evidence
[16]
Ellis AD, McGwin G, Davis GG, Dye DW. Identifying cases of heroin toxicity where 6-acetylmorphine (6-AM) is not detected by toxicological analyses. Forensic science, medicine, and pathology. 2016 Sep:12(3):243-7. doi: 10.1007/s12024-016-9780-2. Epub 2016 Apr 25
[PubMed PMID: 27114260]
Level 3 (low-level) evidence
[17]
Melanson SE, Baskin L, Magnani B, Kwong TC, Dizon A, Wu AH. Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys. Archives of pathology & laboratory medicine. 2010 May:134(5):735-9
[PubMed PMID: 20441504]
Level 3 (low-level) evidence
[18]
Mundin G, McDonald R, Smith K, Harris S, Strang J. Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. Addiction (Abingdon, England). 2017 Sep:112(9):1647-1652. doi: 10.1111/add.13849. Epub 2017 May 28
[PubMed PMID: 28430384]
[19]
Avetian GK, Fiuty P, Mazzella S, Koppa D, Heye V, Hebbar P. Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations. Current medical research and opinion. 2018 Apr:34(4):573-576. doi: 10.1080/03007995.2017.1334637. Epub 2017 Jun 7
[PubMed PMID: 28535115]
Level 3 (low-level) evidence
[20]
Willman MW, Liss DB, Schwarz ES, Mullins ME. Do heroin overdose patients require observation after receiving naloxone? Clinical toxicology (Philadelphia, Pa.). 2017 Feb:55(2):81-87. doi: 10.1080/15563650.2016.1253846. Epub 2016 Nov 16
[PubMed PMID: 27849133]
[21]
Leen JLS, Juurlink DN. Carfentanil: a narrative review of its pharmacology and public health concerns. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2019 Apr:66(4):414-421. doi: 10.1007/s12630-019-01294-y. Epub 2019 Jan 21
[PubMed PMID: 30666589]
Level 3 (low-level) evidence
[22]
Fiorentin TR, Krotulski AJ, Martin DM, Browne T, Triplett J, Conti T, Logan BK. Detection of Cutting Agents in Drug-Positive Seized Exhibits within the United States. Journal of forensic sciences. 2019 May:64(3):888-896. doi: 10.1111/1556-4029.13968. Epub 2018 Nov 28
[PubMed PMID: 30485426]
[23]
Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm reduction journal. 2019 Jan 28:16(1):9. doi: 10.1186/s12954-019-0278-6. Epub 2019 Jan 28
[PubMed PMID: 30691503]
[24]
Smith DE. Medicalizing the Opioid Epidemic in the U.S. in the Era of Health Care Reform. Journal of psychoactive drugs. 2017 Apr-Jun:49(2):95-101. doi: 10.1080/02791072.2017.1295334. Epub 2017 Mar 15
[PubMed PMID: 28296623]
[25]
Fomin D, Baranauskaite V, Usaviciene E, Sumkovskaja A, Laima S, Jasulaitis A, Minkuviene ZN, Chmieliauskas S, Stasiuniene J. Human deaths from drug overdoses with carfentanyl involvement-new rising problem in forensic medicine: A STROBE-compliant retrospective study. Medicine. 2018 Nov:97(48):e13449. doi: 10.1097/MD.0000000000013449. Epub
[PubMed PMID: 30508965]
Level 2 (mid-level) evidence
[26]
Goldberg SA, Dworkis DA, Liao VT, Eyre AJ, Albert J, Fawcett MM, Narovec CM, DiClemente J, Weiner SG. Feasibility of Bystander Administration of Public-Access Naloxone for Opioid Overdose. Prehospital emergency care. 2018 Nov-Dec:22(6):788-794. doi: 10.1080/10903127.2018.1461284. Epub 2018 May 3
[PubMed PMID: 29723076]
Level 2 (mid-level) evidence
[27]
Stam NC, Gerostamoulos D, Smith K, Pilgrim JL, Drummer OH. Challenges with take-home naloxone in reducing heroin mortality: a review of fatal heroin overdose cases in Victoria, Australia. Clinical toxicology (Philadelphia, Pa.). 2019 May:57(5):325-330. doi: 10.1080/15563650.2018.1529319. Epub 2018 Nov 17
[PubMed PMID: 30451007]
Level 3 (low-level) evidence
[28]
Saxon AJ, Akerman SC, Liu CC, Sullivan MA, Silverman BL, Vocci FJ. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. Addiction (Abingdon, England). 2018 Aug:113(8):1477-1487. doi: 10.1111/add.14199. Epub 2018 Apr 1
[PubMed PMID: 29493836]
[29]
Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, Farkas S, Fishman M, Gauthier P, Hodgkins CC, King J, Lindblad R, Liu D, Matthews AG, May J, Peavy KM, Ross S, Salazar D, Schkolnik P, Shmueli-Blumberg D, Stablein D, Subramaniam G, Rotrosen J. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet (London, England). 2018 Jan 27:391(10118):309-318. doi: 10.1016/S0140-6736(17)32812-X. Epub 2017 Nov 14
[PubMed PMID: 29150198]
Level 2 (mid-level) evidence
[30]
Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA psychiatry. 2019 Feb 1:76(2):208-216. doi: 10.1001/jamapsychiatry.2018.3126. Epub
[PubMed PMID: 30516809]
[31]
Huang G, Barnes EW, Peacock JE Jr. Repeat Infective Endocarditis in Persons Who Inject Drugs: "Take Another Little Piece of my Heart". Open forum infectious diseases. 2018 Dec:5(12):ofy304. doi: 10.1093/ofid/ofy304. Epub 2018 Nov 16
[PubMed PMID: 30555849]
[32]
Moiseev VS, Kobalava ZD, Pisaryuk AS, Milto AS, Kotova EO, Karaulova YL, Kahktsyan PV, Chukalin AS, Balatskiy AV, Safarova AF, Ratchina SА, Merai IA, Povalyaev NM. Infective Endocarditis in Moscow General Hospital: Clinical Characteristics and Outcomes (Single-Center 7 Years’ Experience). Kardiologiia. 2018 Dec 25:58(12):66-75. doi: 10.18087/cardio.2018.12.10192. Epub 2018 Dec 25
[PubMed PMID: 30625099]
[33]
Bandaru S, Manthri S, Sundareshan V, Prakash V. Empyema Necessitans in the Setting of Methicillin-Susceptible Staphylococcus aureus Causing Pneumonia and Bacteremia. Case reports in infectious diseases. 2018:2018():4906547. doi: 10.1155/2018/4906547. Epub 2018 Apr 5
[PubMed PMID: 29850305]
Level 3 (low-level) evidence
[34]
Jiang Z, Xiu C, Yang J, Zhang X, Liu M, Chen X, Liu D. HIV test uptake and related factors amongst heterosexual drug users in Shandong province, China. PloS one. 2018:13(10):e0204489. doi: 10.1371/journal.pone.0204489. Epub 2018 Oct 18
[PubMed PMID: 30335766]
[35]
Faul M, Lurie P, Kinsman JM, Dailey MW, Crabaugh C, Sasser SM. Multiple Naloxone Administrations Among Emergency Medical Service Providers is Increasing. Prehospital emergency care. 2017 Jul-Aug:21(4):411-419. doi: 10.1080/10903127.2017.1315203. Epub 2017 May 8
[PubMed PMID: 28481656]
[36]
Chang G, Davids M, Kershaw A. Overdose education and naloxone distribution for veterans with opioid use disorder: Results from a pilot initiative. Journal of addictive diseases. 2017 Oct-Dec:36(4):217-221. doi: 10.1080/10550887.2017.1333331. Epub 2017 May 26
[PubMed PMID: 28548574]
Level 3 (low-level) evidence
[37]
Morton KJ, Harrand B, Floyd CC, Schaefer C, Acosta J, Logan BC, Clark K. Pharmacy-based statewide naloxone distribution: A novel "top-down, bottom-up" approach. Journal of the American Pharmacists Association : JAPhA. 2017 Mar-Apr:57(2S):S99-S106.e5. doi: 10.1016/j.japh.2017.01.017. Epub
[PubMed PMID: 28292508]
[38]
Wakeman SE. Another Senseless Death - The Case for Supervised Injection Facilities. The New England journal of medicine. 2017 Mar 16:376(11):1011-1013. doi: 10.1056/NEJMp1613651. Epub
[PubMed PMID: 28296603]
Level 3 (low-level) evidence
[39]
Ober AJ, Watkins KE, McCullough CM, Setodji CM, Osilla K, Hunter SB. Patient predictors of substance use disorder treatment initiation in primary care. Journal of substance abuse treatment. 2018 Jul:90():64-72. doi: 10.1016/j.jsat.2018.04.004. Epub 2018 Apr 28
[PubMed PMID: 29866385]
[40]
Friedmann PD, Schwartz RP. Just call it "treatment". Addiction science & clinical practice. 2012 Jun 9:7(1):10. doi: 10.1186/1940-0640-7-10. Epub 2012 Jun 9
[PubMed PMID: 23186149]